Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back

Neurotherapeutics

Volumn 12, Issue 3, 2015, Pages 584-608

  Gross, Christina ^a   Hoffmann, Anne ^b   Bassell, Gary J ^c   Berry Kravis, Elizabeth M ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; clinical trials; FMRP; Fragile X syndrome; language development; mRNA translation

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARBACLOFEN; BASIMGLURANT; BIOLOGICAL MARKER; DONEPEZIL; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; GANAXOLONE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LITHIUM; MAVOGLURANT; MESSENGER RNA; METADOXINE; MEVINOLIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; PLACEBO; RNA BINDING PROTEIN; SEROTONIN UPTAKE INHIBITOR; TRINUCLEOTIDE; VOLTAGE GATED CALCIUM CHANNEL; FMR1 PROTEIN, HUMAN;

ANXIETY DISORDER; AUTISM; BEHAVIOR DISORDER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COGNITIVE THERAPY; FRAGILE X SYNDROME; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LANGUAGE DISABILITY; MISSENSE MUTATION; NERVE CELL; NERVE CELL NETWORK; NEUROLOGIC DISEASE; NONHUMAN; OCCUPATIONAL THERAPY; PHENOTYPE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPEECH THERAPY; TREATMENT INDICATION; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; MUTATION; TRANSLATIONAL RESEARCH;

ANIMALS; AUTISM SPECTRUM DISORDER; BIOMARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTATION; NEURONS; PHENOTYPE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84937630810     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0355-9     Document Type: Review

References (238)

1. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009;85:503-514.
2. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. Clin Genet 2011;80:214-225.
3. Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet 2012;159B:589-597.
4. Tassone F, Iong KP, Tong T-H, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012;4:100.
5. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123:378-390.
6. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004;10:31-41.
7. Kidd SA LA, Barbouth D, et al. Fragile X syndrome: a review of associated medical problems. Pediatrics 2014;134:995-1005.
8. Kaufmann WE, Abrams MT, Chen W, Reiss AL. Genotype, molecular phenotype, and cognitive phenotype: Correlations in fragile X syndrome. Am J Med Genet 1999;83:286.
9. de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996;58:1025.
10. Freund LS, Reiss AL, Abrams MT. Psychiatric Disorders Associated With Fragile X in the Young Female. Pediatrics. 1993;91(2):321.
11. Dykens EM, Hodapp RM, Leckman JF. Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. Am J Ment Defic 1987;92:234.
12. Fisch GS, Carpenter N, Holden JJA, et al. Longitudinal changes in cognitive and adaptive behavior in fragile X females: A prospective multicenter analysis. Am J Med Genet 1999;83:308.
13. Fisch GS, Simensen R, Tarleton J, et al. Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: A prospective multicenter analysis. Am J Med Genet 1996;64:356.
14. Klaiman C, Quintin E-M, Jo B, et al. Longitudinal profiles of adaptive behavior in fragile X syndrome. Pediatrics 2014;134:315-324.
15. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995;95:744.
16. Hagerman RJ, Falkenstein AR. An association between recurrent otitis media in infancy and later hyperactivity. Clin Pediatr (Phila) 1987;26:253-257.
17. Hagerman RJ, Jackson C, Amiri K, O’Connor R, Sobesky W, Silverman AC. Girls with fragile X syndrome: physical and neurocognitive status and outcome. Pediatrics 1992;89:395-400.
18. Mazzocco MM, Pennington BF, Hagerman RJ. The neurocognitive phenotype of female carriers of fragile X: additional evidence for specificity. J Dev Behav Pediatr 1993;14:328-335.
19. Turk J. Fragile X syndrome and attentional deficits. J Appl Res Intellect Disabil 1998;11:175.
20. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011;3:57-67.
21. Cohen IL. A theoretical analysis of the role of hyperarousal in the learning and behavior of fragile X males. Ment Retard Dev Disabil Res Rev 1995;1:286-291.
22. Bailey DJ, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile x syndrome. J Autism Dev Disord 1998;28:499-508.
23. Belser RC, Sudhalter V. Conversational characteristics of children with fragile X syndrome: repetitive speech. Am J Ment Retard 2001;106:28-38.
24. Symons FJ, Byiers BJ, Raspa M, Bishop E, Bailey Jr DB. Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey. Am J Intellect Dev Disabil 2010;115:473-481.
25. Bailey Jr DB, Raspa M, Bishop E, et al. Health and economic consequences of fragile X syndrome for caregivers. J Dev Behav Pediatr 2012;33:705-712.
26. Brady N, Skinner D, Roberts J, Hennon E. Communication in young children with fragile X syndrome: A qualitative study of mothers’ perspectives. Am J Speech Lang Pathol 2006;15:353-364.
27. Roberts JE, Mirrett P, Burchinal M. Receptive and expressive communication development of young males with fragile X syndrome. Am J Ment Retard 2001;106:216-230.
28. Roberts JE, Mirrett P, Anderson K, Burchinal M, Neebe E. Early communication, symbolic behavior, and social profiles of young males with fragile X syndrome. Am J Speech Lang Pathol 2002;11:295-304.
29. Abbeduto L, Hagerman RJ. Language and communication in fragile X syndrome. Ment Ret Dev Dis Res Rev 1997;3:313.
30. Lewis P, Abbeduto L, Murphy M, et al. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res 2006;50:532-545.
31. McDuffie A, Kover S, Abbeduto L, Lewis P, Brown T. Profiles of receptive and expressive language abilities in boys with comorbid fragile X syndrome and autism. Am J Intellect Dev Disabil 2012;117:18.
32. Murphy MM, Abbeduto L. Indirect genetic effects and the early language development of children with genetic mental retardation syndromes: The role of joint attention. Infants Young Children 2005;18:47-59.
33. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010;7:264-274.
34. Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. International J of Pediatrics 2012.
35. Abbeduto L, McDuffie A, Thurman AJ. The fragile X syndrome–autism comorbidity: what do we really know? Front Genet 2014;5:355.
36. Ozonoff S, Heung K, Byrd R, Hansen R, Hertz‐Picciotto I. The onset of autism: patterns of symptom emergence in the first years of life. Autism Res 2008;1:320-328.
37. Hessl D, Dyer-Friedman J, Glaser B, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics 2001;108:E88.
38. Bailey DB, Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Ped 2012;33:62-69.
39. Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 2013;16:1530-1536.
40. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 2012;7:219-245.
41. Zang JB, Nosyreva ED, Spencer CM, et al. A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet 2009;5:e1000758.
42. Myrick LK, Nakamoto-Kinoshita M, Lindor NM, Kirmani S, Cheng X, Warren ST. Fragile X syndrome due to a missense mutation. Eur J Hum Genet 2014;22:1185-1189.
43. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A 2007;104:15537-15542.
44. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001;107:489-499.
45. Menon L, Mader SA, Mihailescu MR. Fragile X mental retardation protein interactions with the microtubule associated protein 1B RNA. RNA 2008;14:1644-1655.
46. Menon L, Mihailescu MR. Interactions of the G quartet forming semaphorin 3F RNA with the RGG box domain of the fragile X protein family. Nucleic Acids Res 2007;35:5379-5392.
47. Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J 2001;20:4803-4813.
48. Subramanian M, Rage F, Tabet R, Flatter E, Mandel JL, Moine H. G-quadruplex RNA structure as a signal for neurite mRNA targeting. EMBO Rep 2011;12:697-704.
49. Dictenberg JB, Swanger SA, Antar LB, Singer RH, Bassell GJ. A direct role for FMRP in activity dependent dendritic mRNA transport links filopodial spine morphogenesis to fragile x syndrome. Dev Cell 2008;14:926-939.
50. Myrick LK, Hashimoto H, Cheng X, Warren ST. Human FMRP contains an integral tandem Agenet (Tudor) and KH motif in the amino terminal domain. Hum Mol Genet 2015;24:1733-1740.
51. Zalfa F, Adinolfi S, Napoli I, et al. Fragile X mental retardation protein (FMRP) binds specifically to the brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. J Biol Chem 2005;280:33403-33410.
52. Zalfa F, Giorgi M, Primerano B, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003;112:317-327.
53. Napoli I, Mercaldo V, Boyl PP, et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008;134:1042-1054.
54. Myrick LK, Deng PY, Hashimoto H, et al. Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures. Proc Natl Acad Sci U S A 2015;112:949-956.
55. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST. FMRP: Nucleocytoplasmic shuttling and association with somatodendritic polyribosomes. J Neurosci 1997;17:1539-1547.
56. Kim M, Bellini M, Ceman S. Fragile X mental retardation protein FMRP binds mRNAs in the nucleus. Mol Cell Biol 2009;29:214-228.
57. Bhogal B, Jepson JE, Savva YA, Pepper AS, Reenan RA, Jongens TA. Modulation of dADAR-dependent RNA editing by the Drosophila fragile X mental retardation protein. Nat Neurosci 2011;14:1517-1524.
58. Bassell GJ. Fragile balance: RNA editing tunes the synapse. Nat Neurosci 2011;14:1492-1494.
59. Dury AY, El Fatimy R, Tremblay S, et al. Nuclear fragile X mental retardation protein is localized to Cajal bodies. PLoS Genet 2013;9:e1003890.
60. Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, et al. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell 2014;157:869-881.
61. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 2007;27:5338-5348.
62. Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010;30:10624-10638.
63. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 2010;30:15616-15627.
64. Gross C, Bassell GJ. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol Med 2012;18:336-345.
65. Hoeffer CA, Sanchez E, Hagerman RJ, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav 2012;11:332-341.
66. Kumari D, Bhattacharya A, Nadel J, et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum Mutat 2014;35:1485-1494.
67. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011;146:247-261.
68. Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S. Fragile X mental retardation protein regulates translation by binding directly to the ribosome. Mol Cell 2014;54:407-417.
69. Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science 1993;262:563-566.
70. Ray D, Kazan H, Cook KB, et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 2013;499:172-177.
71. Ascano M, Jr., Mukherjee N, Bandaru P, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012;492:382-386.
72. Suhl JA, Chopra P, Anderson BR, Bassell GJ, Warren ST. Analysis of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences. Hum Mol Genet 2014;23:5479-5491.
73. Bechara EG, Didiot MC, Melko M, et al. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 2009;7:e16.
74. Gross C, Yao X, Pong DL, Jeromin A, Bassell GJ. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J Neurosci 2011;31:5693-5698.
75. Kwan KY, Lam MM, Johnson MB, et al. Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell 2012;149:899-911.
76. Fahling M, Mrowka R, Steege A, et al. Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J Biol Chem 2009;284:4255-4266.
77. Ceman S, O’Donnell WT, Reed M, Patton S, Pohl J, Warren ST. Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum Mol Genet 2003;12:3295-3305.
78. Narayanan U, Nalavadi V, Nakamoto M, et al. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J Biol Chem 2008;283:18478-18482.
79. Muddashetty RS, Nalavadi VC, Gross C, et al. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol Cell 2011;42:673-688.
80. Niere F, Wilkerson JR, Huber KM. Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 2012;32:5924-5936.
81. Coffee RL, Jr., Williamson AJ, Adkins CM, Gray MC, Page TL, Broadie K. In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation. Hum Mol Genet 2012;21:900-915.
82. Narayanan U, Nalavadi V, Nakamoto M, et al. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J Neurosci 2007;27:14349-14357.
83. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006;51:441-454.
84. Nalavadi VC, Muddashetty RS, Gross C, Bassell GJ. Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation. J Neurosci 2012;32:2582-2587.
85. Edbauer D, Neilson JR, Foster KA, et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010;65:373-384.
86. Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004;6:1048-1053.
87. Jin P, Zarnescu DC, Ceman S, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004;7:113-117.
88. Xu XL, Li Y, Wang F, Gao FB. The steady-state level of the nervous-system-specific microRNA-124a is regulated by dFMR1 in Drosophila. J Neurosci 2008;28:11883-11889.
89. Yang Y, Xu S, Xia L, et al. The bantam microRNA is associated with Drosophila fragile X mental retardation protein and regulates the fate of germline stem cells. PLoS Genet 2009;5:e1000444.
90. Cheever A, Ceman S. Translation regulation of mRNAs by the fragile X family of proteins through the microRNA pathway. RNA Biol 2009;6:175-178.
91. Stefanovic S, Bassell GJ, Mihailescu MR. G quadruplex RNA structures in PSD-95 mRNA: potential regulators of miR-125a seed binding site accessibility. RNA 2015;21:48-60.
92. Li Y, Tang W, Zhang LR, Zhang CY. FMRP regulates miR196a-mediated repression of HOXB8 via interaction with the AGO2 MID domain. Mol Biosyst 2014;10:1757-1764.
93. Liu T, Wan RP, Tang LJ, et al. A microRNA profile in Fmr1 knockout mice reveals microRNA expression alterations with possible roles in fragile X syndrome. Mol Neurobiol 2014 Jun 7 [Epub ahead of print].
94. Kenny PJ, Zhou H, Kim M, et al. MOV10 and FMRP regulate AGO2 association with microRNA recognition elements. Cell Rep 2014;9:1729-1741.
95. Goncalves JT, Anstey JE, Golshani P, Portera-Cailliau C. Circuit level defects in the developing neocortex of Fragile X mice. Nat Neurosci 2013;16:903-909.
96. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol 2008;100:2615-2626.
97. Hays SA, Huber KM, Gibson JR. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J Neurosci 2011;31:14223-14234.
98. Zhang Y, Bonnan A, Bony G, et al. Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1(-/y) mice. Nat Neurosci 2014;17:1701-1709.
99. Brager DH, Johnston D. Channelopathies and dendritic dysfunction in fragile X syndrome. Brain Res Bull 2014;103:11-17.
100. Brown V, Jin P, Ceman S, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001;107:477-487.
101. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 2003;120:1005-1017.
102. Strumbos JG, Brown MR, Kronengold J, Polley DB, Kaczmarek LK. Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. J Neurosci 2010;30:10263-10271.
103. Lee HY, Ge WP, Huang W, et al. Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 2011;72:630-642.
104. Routh BN, Johnston D, Brager DH. Loss of functional A-type potassium channels in the dendrites of CA1 pyramidal neurons from a mouse model of fragile X syndrome. J Neurosci 2013;33:19442-19450.
105. Brown MR, Kronengold J, Gazula VR, et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci 2010;13:819-821.
106. Zhang Y, Brown MR, Hyland C, et al. Regulation of neuronal excitability by interaction of fragile X mental retardation protein with slack potassium channels. J Neurosci 2012;32:15318-15327.
107. Deng PY, Rotman Z, Blundon JA, et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 2013;77:696-711.
108. Ferron L, Nieto-Rostro M, Cassidy JS, Dolphin AC. Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density. Nat Commun 2014;5:3628.
109. Anon. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch–Belgian Fragile X Consortium. Cell 1994;78:23-33.
110. Mientjes EJ, Nieuwenhuizen I, Kirkpatrick L, et al. The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 2006;21:549-555.
111. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012;76:325-337.
112. Osterweil EK, Chuang SC, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013;77:243-250.
113. Liu ZH, Huang T, Smith CB. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis 2012;45:1145-1152.
114. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012;4:152ra128.
115. Lim CS, Hoang ET, Viar KE, Stornetta RL, Scott MM, Zhu JJ. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev 2014;28:273-289.
116. Guo W, Murthy AC, Zhang L, et al. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 2012;21:681-691.
117. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron 2007;56:955-962.
118. Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res 2011;223:310-321.
119. de Esch CE, van den Berg WE, Buijsen RA, et al. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test. Neurobiol Dis 2015;75:31-39.
120. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56.
121. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 2013;19:603-607.
122. Min WW, Yuskaitis CJ, Yan Q, et al. Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009;56:463-472.
123. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010;79:632-646.
124. Wang GX, Smith SJ, Mourrain P. Fmr1 KO and fenobam treatment differentially impact distinct synapse populations of mouse neocortex. Neuron 2014;84:1273-1286.
125. Levenga J, Hayashi S, de Vrij FM, et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011;42:311-317.
126. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31:127-132.
127. Pop AS, Levenga J, de Esch CE, et al. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology (Berl) 2014;231:1227-1235.
128. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci 2010;107:11591-11596.
129. Michalon A, Bruns A, Risterucci C, et al. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice. Biol Psychiatry 2014;75:189-197.
130. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49:1053-1066.
131. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 2012;219:47-58.
132. Gantois I, Pop AS, de Esch CE, et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 2013;239:72-79.
133. Vinueza Veloz MF, Buijsen RA, Willemsen R, et al. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 2012;11:325-331.
134. Franklin AV, King MK, Palomo V, Martinez A, McMahon LL, Jope RS. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry 2014;75:198-206.
135. Volk LJ, Daly CA, Huber KM. Differential roles for group 1 mGluR subtypes in induction and expression of chemically induced hippocampal long-term depression. J Neurophysiol 2006;95:2427-2438.
136. Veeraragavan S, Graham D, Bui N, Yuva-Paylor LA, Wess J, Paylor R. Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS). Behav Brain Res 2012;228:1-8.
137. Veeraragavan S, Bui N, Perkins JR, Yuva-Paylor LA, Carpenter RL, Paylor R. Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) 2011;217:143-151.
138. Veeraragavan S, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav Neurosci 2011;125:783-790.
139. Choi CH, Schoenfeld BP, Bell AJ, et al. Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res 2011;1380:106-119.
140. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010;30:9929-9938.
141. Heulens I, D’Hulst C, Braat S, Rooms L, Kooy RF. Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome. ScientificWorldJournal 2010;10:2198-2206.
142. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci 2011;33:395-403.
143. Pacey LK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 2009;76:18-24.
144. Wang H, Wu LJ, Kim SS, et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008;59:634-647.
145. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol 2004;15:433-442.
146. Costa L, Spatuzza M, D’Antoni S, et al. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 2012;72:924-933.
147. Tian M, Zeng Y, Hu Y, et al. 7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome. Neuropharmacology 2015;89:43-53.
148. Lauterborn JC, Rex CS, Kramar E, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007;27:10685-10694.
149. Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One 2012;7:e36981.
150. Ronesi JA, Collins KA, Hays SA, et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci 2012;15:431-440.
151. Pacey LK, Doss L, Cifelli C, der Kooy DV, Heximer SP, Hampson DR. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol Cell Neurosci 2011;46:563-572.
152. Swanger SA, Yao X, Gross C, Bassell GJ. Automated 4D analysis of dendritic spine morphology: applications to stimulus-induced spine remodeling and pharmacological rescue in a disease model. Mol Brain 2011;4:38.
153. Liu Z-H, Chuang D-M, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2011;14:618-630.
154. Chen X, Sun W, Pan Y, et al. Lithium ameliorates open-field and elevated plus maze behaviors, and brain phospho-glycogen synthase kinase 3-beta expression in fragile X syndrome model mice. Neurosciences 2013;18:356-362.
155. Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 2010;5:e9706.
156. Hayashi ML, Rao BS, Seo JS, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A 2007;104:11489-11494.
157. Dolan BM, Duron SG, Campbell DA, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A 2013;110:5671-5676.
158. Choi CH, Schoenfeld BP, Weisz ED, et al. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci 2015;35:396-408.
159. Boda B, Mendez P, Boury-Jamot B, Magara F, Muller D. Reversal of activity-mediated spine dynamics and learning impairment in a mouse model of fragile X syndrome. Eur J Neurosci 2014;39:1130-1137.
160. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011;480:63-68.
161. Udagawa T, Farny NG, Jakovcevski M, et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med 2013;19:1473-1477.
162. Westmark CJ, Westmark PR, O’Riordan KJ, et al. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 2011;6:e26549.
163. Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci 2014;34:9867-9879.
164. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009;46:94-102.
165. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav 2012;11:586-600.
166. Hebert B, Pietropaolo S, Meme S, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule. Orphanet J Rare Dis 2014;9:124.
167. Choi CH, McBride SM, Schoenfeld BP, et al. Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue. Biogerontology 2010;11:347-362.
168. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008;4:256-263.
169. Gatto CL, Pereira D, Broadie K. GABAergic circuit dysfunction in the Drosophila fragile X syndrome model. Neurobiol Dis 2014;65:142-159.
170. Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011;4:673-685.
171. Irwin SA, Patel B, Idupulapati M, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 2001;98:161-167.
172. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002;99:7746-7750.
173. Nosyreva ED, Huber KM. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 2006;95:3291-3295.
174. Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr 2007;28:133-138.
175. Hagerman PJ, Stafstrom CE. Origins of epilepsy in fragile x syndrome. Epilepsy Curr 2009;9:108-112.
176. Hessl D, Berry-Kravis E, Cordeiro L, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet 2009;150B:545-553.
177. King MK, Jope RS. Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav 2013;12:723-731.
178. Gandhi RM, Kogan CS, Messier C. 2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. Front Cell Neurosci 2014;8:70.
179. Bernardet M, Crusio WE. Fmr1 KO mice as a possible model of autistic features. ScientificWorldJournal 2006;6:1164-1176.
180. Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res 2014;3:118-133.
181. Zhang YQ, Bailey AM, Matthies HJ, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 2001;107:591-603.
182. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005;45:753-764.
183. Ng MC, Yang YL, Lu KT. Behavioral and synaptic circuit features in a zebrafish model of fragile X syndrome. PLoS One 2013;8:e51456.
184. Kim L, He L, Maaswinkel H, Zhu L, Sirotkin H, Weng W. Anxiety, hyperactivity and stereotypy in a zebrafish model of fragile X syndrome and autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 2014;55:40-49.
185. Gross C, Berry-Kravis EM, Bassell GJ. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 2012;37:178-195.
186. Kim SH, Markham JA, Weiler IJ, Greenough WT. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc Natl Acad Sci U S A 2008;105:4429-4434.
187. Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1253-1257.
188. Kovacs T, Bansagi B, Kelemen O, Keri S. Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications. J Mol Neurosci 2014;54:119-124.
189. Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013;161A:1897-1903.
190. Erickson CA, Ray B, Maloney B, et al. Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res 2014;59:220-228.
191. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res 2011;1380:264-270.
192. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008;29:293-302.
193. Irwin SA, Idupulapati M, Gilbert ME, et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet 2002;111:140-146.
194. Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for fragile X syndrome. Curr Opin Pharmacol 2015;20C:124-134.
195. Cruz-Martin A, Crespo M, Portera-Cailliau C. Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 2010;30:7793-7803.
196. Cruz-Martin A, Crespo M, Portera-Cailliau C. Glutamate induces the elongation of early dendritic protrusions via mGluRs in wild type mice, but not in fragile X mice. PLoS One 2012;7:e32446.
197. Smith LN, Jedynak JP, Fontenot MR, et al. Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration. Neuron 2014;82:645-658.
198. Pan F, Aldridge GM, Greenough WT, Gan WB. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A 2010;107:17768-17773.
199. Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006;16:525-540.
200. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008;29:293-302.
201. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-271.
202. Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet Part A 2009;149:403-407.
203. 2015 [cited January 21, 2015]. Available from: www.clinicaltrials.gov.
204. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91.
205. Leigh MJS, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013;34:147-155.
206. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1.
207. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4:152ra127.
208. Berry-Kravis E, Visootsak J, Hagerman R, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. Ann Neurol 2014;76:174.
209. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013;228:75-84.
210. Mullard A. Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov 2015;14:151-153.
211. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 2004;3:337-359.
212. Oddi D, Subashi E, Middei S, et al. Early social enrichment rescues adult behavioral and brain abnormalities in a mouse model of fragile X syndrome. Neuropsychopharmacology 2015;40:1113-1122.
213. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 1999;94:185-192.
214. Seese RR, Wang K, Yao YQ, Lynch G, Gall CM. Spaced training rescues memory and ERK1/2 signaling in fragile X syndrome model mice. Proc Natl Acad Sci U S A 2014;111:16907-16912.
215. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A 2011;108:2587-2592.
216. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370-377.
217. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci 2007;27:11624-11634.
218. Pacey LK, Doss L, Cifelli C, van der Kooy D, Heximer SP, Hampson DR. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol Cell Neurosci 2011;46:563-572.
219. Kelley DJ, Bhattacharyya A, Lahvis GP, Yin JC, Malter J, Davidson RJ. The cyclic AMP phenotype of fragile X and autism. Neurosci Biobehav Rev 2008;32:1533-1543.
220. Bolduc FV, Bell K, Cox H, Broadie KS, Tully T. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat Neurosci 2008;11:1143-1145.
221. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010;30:694-702.
222. Spencer CM, Alekseyenko O, Hamilton SM, et al. Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res 2011;4:40-56.
223. Engineer CT, Centanni TM, Im KW, Rahebi KC, Buell EP, Kilgard MP. Degraded speech sound processing in a rat model of fragile X syndrome. Brain Res 2014;1564:72-84.
224. Hamilton SM, Green JR, Veeraragavan S, et al. Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders. Behav Neurosci 2014;128:103-109.
225. Chailangkarn T, Acab A, Muotri AR. Modeling neurodevelopmental disorders using human neurons. Curr Opin Neurobiol 2012;22:785-790.
226. Liu J, Koscielska KA, Cao Z, et al. Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet 2012;21:3795-3805.
227. Sheridan SD, Theriault KM, Reis SA, et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011;6:e26203.
228. de Esch CE, Ghazvini M, Loos F, et al. Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation. Stem Cell Rep 2014;3:548-555.
229. Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol 2014;50:297-302.
230. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord 2011;3:193-210.
231. De Sonia A, Visootsak J, Smith M, et al. FXCRC analysis of arbaclofen responses in fragile X syndrome. In: Proceedings of the 14th International Fragile X Conference, Orange County, CA, 2004.
232. Berry-Kravis E, Hessl D, Abbeduto L, et al. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 2013;34:508-522.
233. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014;231:1237-1250.
234. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012;74:285-299.
235. Steinberg J, Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies. Am J Hum Genet 2013;93:825-839.
236. Waltes R, Duketis E, Knapp M, et al. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet 2014;133:781-792.
237. Gross C, Raj N, Molinaro G, Allen Amanda G, Whyte Alonzo J, Gibson Jay R, et al. Selective Role of the Catalytic PI3K Subunit p110β in Impaired Higher Order Cognition in Fragile X Syndrome. Cell reports. 2015
238. Gross C, Chang C-W, Kelly Seth M, Bhattacharya A, McBride Sean MJ, Danielson Scott W, et al. Increased Expression of the PI3K Enhancer PIKE Mediates Deficits in Synaptic Plasticity and Behavior in Fragile X Syndrome. Cell reports. 2015